PTC THERAPEUTICS, INC.

0001070081 false 0001070081 2026-06-02 2026-06-02 ​ ​ UNITED STATES ​ SECURITIES AND EXCHANGE COMMISSION ​ WASHINGTON, D.C. 20549 ​ FORM 8-K ​ CURRENT REPORT ​ Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): June 2, 2026 ​ PTC THERAPEUTICS, INC. ​ (Exact Name of Company as Specified in Charter) ​ ​ ​ ​ ​ ​ Delaware ​ ​ ​ 001-35969 ​ ​ ​ 04-3416587 (State or Other Jurisdiction ​ (Commission ​ (IRS Employer of Incorporation) ​ File Number) ​ Identification No.) ​ ​ ​ ​ ​ ​ 500 Warren Corporate Center Drive ​ ​ ​ ​ ​ Warren , NJ ​ ​ 07059 (Address of Principal Executive Offices) ​ ​ (Zip Code) ​ Registrant’s telephone number, including area code: ( 908 ) 222-7000 ​ Not applicable (Former Name or Former Address, if Changed Since Last Report) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​ Title of each class ​ ​ ​ Trading Symbol(s) ​ ​ ​ Name of each exchange on which registered Common Stock, $0.001 par value per share ​ PTCT ​ Nasdaq Global Select Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting on June 2, 2026 (the “Annual Meeting”). The results for the votes regarding each proposal at the Annual Meeting are set forth below. As of the record date of the Annual Meeting, April 10, 2026, there were 82,911,783 shares of the Company’s common stock outstanding. Each share of common stock entitled its holder to one vote per share. The stockholders of the Company elected four Class I directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his or her successor has been duly elected and qualified, as follows: ​ ​ ​ ​ Director For Withheld Broker Non-Votes Jessica Chutter 71,945,515 737,780 3,858,311 Matthew B. Klein, M.D., M.S., F.A.C.S. 71,550,878 1,132,417 3,858,311 Stephanie S. Okey, M.S. 68,902,707 3,780,588 3,858,311 Jerome B. Zeldis, M.D., Ph.D. 69,821,943 2,861,352 3,858,311 The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s stockholders with 76,170,292 votes “For,” 355,794 votes “Against,” and 15,520 votes “Abstained.” The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders with 71,166,204 votes “For,” 1,492,801 votes “Against,” 24,290 votes “Abstained,” and 3,858,311 broker non-votes. ​ ​ ​ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​ ​ ​ PTC Therapeutics, Inc. ​ ​ Date: June 5, 2026 By: /s/ Pierre Gravier ​ Name: Pierre Gravier ​ Title: Chief Financial Officer ​ ​